TY  - CHAP
M1  - Book, Section
TI  - Ovarian Cancer
A1  - Smith, Judith A.
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Lee, Kelly C.
A2  - Bookstaver, P. Brandon
PY  - 2018
T2  - Pharmacotherapy Principles and Practice, 5e
AB  - Content  UpdateMay  28,  2020Selpercatinib  Approved  for  Treatment  of  RET  Fusion-Positive  Non-small-cell  Lung  Cancer  (NSCLC)  And  Thyroid  Cancer:Selpercatinib  (Retevmo)  is  indicated  for  adults  with  RET  fusion-positive  NSCLC  and  adults  and  children  older  than  age  12  with  RET  fusion-positive  thyroid  cancer.  A  trial  involving  144  patients  with  NSCLC  and  143  patients  with  thyroid  cancer  who  had  advanced  or  metastatic  RET  fusion-positive  disease  gave  patients  selpercatinib  160  mg  orally  twice  a  day.  The  overall  response  rate  was  64%  (95%  CI:  54%,  73%)  in  NSCLC  patients  who  received  prior  therapy,  69%  (95%  CI:  55%,  81%)  in  treatment-naïve  individuals,  and  73%  (95%  CI:  62%,  82%)  in  treatment-naïve  patients  with  thyroid  cancer.  Common  adverse  effects  were  diarrhea  and  hypertension.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - ppp.mhmedical.com/content.aspx?aid=1174273301
ER  -